{"title":"Kalevi Kairemo","description":"\u003cp\u003e\u003c\/p\u003e\u003cp\u003eProf Kairemo graduated with a MSc (Eng) degree from Helsinki University of Technology (Chemical Engineering) in 1980 before undertaking medical training (MD (86), PhD (93)) at the University of Helsinki, Finland. He undertook specialist training in Clinical Chemistry (94), Nuclear Medicine (96), Health Care Administration (02) and Pharmaceutical Medicine (06) at Helsinki University Central Hospital. He had a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center in 1989-93 in New York. Besides homeland Finland he is licensed medical specialist in Norway (1998), Sweden (2001) and Estonia (2010).\u003c\/p\u003e\u003cbr\u003e\u003cp\u003eProf Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). In 2009-2018, he has been the Chief of Nuclear Medicine and Molecular Radiotherapy (Theragnostics) at the Docrates Cancer Center, in Helsinki. Since 2015 he has acted as Visiting Professor in the Nuclear Medicine Department of The University of Texas MD Anderson Cancer Center, in Houston, TX; last visits in 2019, 2022 and 2023.\u003c\/p\u003e\u003cbr\u003e\u003cp\u003eProf Kairemo has also held posts in industry, as Medical Director of \u003cem\u003eCTT Cancer Targeting Technologies Oy\u003c\/em\u003e (2001-6), Medical Director of \u003cem\u003eImanext Oy\u003c\/em\u003e (2006-8) and Clinical Director at \u003cem\u003eAdvanced Accelerator Applications\u003c\/em\u003e SA in 2009 (now Novartis Co.).\u003c\/p\u003e\u003cbr\u003e\u003cp\u003eBesides a few patents prof Kairemo has published more than 250 original publications in peer-reviewed journals. He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy in 2012 and was President of the 7\u003csup\u003eth\u003c\/sup\u003e International Conference on Radiopharmaceutical Therapy held in November 2012 in Levi in Finnish Lapland. In 2014, Dr Kairemo hosted ISORBE Symposium and Workshop “Cell Labelling and Cell Therapies” in Helsinki. He also organized the 14\u003csup\u003eth\u003c\/sup\u003e International Symposium on Radiopharmaceutical Therapy (WARMTH) in November 2018 in Helsinki. He was elected in 2022 as the new President of the WARMTH for 2024-2025.\u003c\/p\u003e","products":[{"product_id":"prostate-cancer-from-a-nuclear-oncology-perspective-kalevi-kairemo-ebook","title":"Prostate Cancer from a Nuclear Oncology Perspective","description":"\u003cdiv\u003e1. Introduction – prostate cancer from the point of view of the author and the history of imaging.- 2. Integrated summary of research on radioiodinated estramustine phosphate and estramustine binding protein antibody in prostate cancer treatment.- 3. Summary of Diagnostic Accuracy of 18F-Fluorocholine PET\/CT in Prostate Cancer Staging.- 4. Overview of 18F-NaF PET\/CT Imaging.- 5. 18F-Fluciclovine (18F-FACBC) Positron Emission Tomography in Prostate Cancer.- 6. PSMA-PET in prostate cancer.- 7. 18F-FLT PET\/CT in Prostate Adenocarcinoma .- 8. 18F-FDHT-PET Imaging in the Management of Hormone-Dependent  Prostate Cancer.- 9. Immunoscintigraphy and radioimmunotherapy of prostate cancer incuding own personal journey -anti-PAP and anti-PSMA antibodies.- 10. Briefly about radiation therapy.- 11. PET\/CT for Radiation Therapy Planning of Prostate Cancer .- 12. Brief overview of prostate cancer treatment modalities.- 13. Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer.- 14. Lu-177-PSMA treatment in prostate cancer.- 15. Clinical Experience in 225Ac-PSMA.- 16. Multicenter trials prostate radioligand therapy (PRLT) in castration resistant cancer.- 17. Meta-analyses and systematic reviews (own experience) in prostate cancer.- 18. Own history of cancer suspicions.- 19. Public appearance because of nuclear oncology (pictorial essay).- . Appendix - ISUP and PI-RADS classifications.\u003c\/div\u003e","brand":"Kalevi Kairemo","offers":[{"title":"Default Title","offer_id":53652025704775,"sku":"9783031903373","price":128.39,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0920\/5455\/2903\/files\/prostate-cancer-from-a-nuclear-oncology-perspectiv-ebook-cover.webp?v=1775341210"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0920\/5455\/2903\/collections\/kalevi-kairemo-autor-kollektion.webp?v=1775341207","url":"https:\/\/www.cinebuch.de\/collections\/kalevi-kairemo.oembed","provider":"CineBuch","version":"1.0","type":"link"}